PolyPeptide Group AG’s IPO on SIX Swiss Exchange

•

By

CapLaw

Share on:

On 29 April 2021, PolyPeptide Group commenced trading on SIX Swiss Exchange. The offering consisted of 3,125,000 new shares as well as 8,396,740 existing shares offered by PolyPeptide’s sole shareholder, Draupnir Holding B.V., at an offer price of CHF 64.00 per share (with an over-allotment option of up to 1,728,261 existing shares), which implies a total placement volume of up to CHF 848m. Trading opened at CHF 72.50 and closed on the first trading day at CHF 78.20, which represents a rise of more than 22 per cent from the offer price and implies a total market capitalization of CHF 2.59bn.

PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products. Dating back to 1952, PolyPeptide today manufactures around one-half of all currently approved peptide drug substances with a global footprint of six GMP-certified facilities in Europe, the U.S. and India. As a multinational company with more than 900 employees, its diversity brings breadth, depth of knowledge and experience to the group. PolyPeptide has grown organically and by selective acquisition of existing expertise, culminating in its position today as a leader in outsourced peptide manufacturing.

Back to the homepage
CapLaw Themes
CapLaw PDF Archive

Discover more articles

We provide up-to-date information on legal and regulatory developments regarding the capital markets, publish concise articles on developments in the Swiss and international financial markets, and announce recent deals and forthcoming events.

  • FinSA Conduct Obligations: FINMA‘sRecent Enforcement Activity

    By

    Patrick Schärli

    /

    Laura Wälchli

    FINMA has intensified its enforcement of the conduct obligations governing individual financial services under the Financial Services Act (FinSA). The publicly communicated conclusions of two recent enforcement proceedings are good examples of interventions by the regulator under the FinSA conduct regime. Accompanied by FINMA Guidance 03/2026, which highlights recurring risk patterns, these cases signal that the conduct obligations are now firmly on FINMA‘s enforcement radar.

    Read more: FinSA Conduct Obligations: FINMA‘sRecent Enforcement Activity

  • KAPITALMARKTRECHT IM FOKUS 2026 – CONFERENCE REPORT | 19 August 2026, SIX ConventionPoint, Zurich

    By

    Sandro Fehlmann

    /

    Benjamin Leisinger

    /

    Nina Reiser

    On 19 August 2026, practitioners, academics and market participants convened at SIX ConventionPoint in Zurich for Kapitalmarktrecht im Fokus 2026. Under the Title “Clarity or Room for Interpretation? Challenges in Interpreting Bond Terms and Conditions“ (Klarheit oder Auslegungsspielraum? Herausforderungen bei der Interpretation von Anleihensbedingungen), the conference examined how standardized bond terms should be interpreted, the interaction between contractual provisions and regulatory requirements and the significance of prospectuses, risk factors and changing market practice. Particular attention was paid to regulatory capital instruments and the Point of Non-Viability (PONV), against the background of the write-down of Credit Suisse AT1 instruments and the…

    Read more: KAPITALMARKTRECHT IM FOKUS 2026 – CONFERENCE REPORT | 19 August 2026, SIX ConventionPoint, Zurich

  • EHRA CLARIFIES REGISTRATION PRACTICE FOR CONDITIONAL CAPITAL WITHIN AND OUTSIDE THE CAPITAL BAND 

    By

    Samuel Hochstrasser

    In a practice note dated 27 August 2026, the Federal Commercial Register Office (EHRA) clarified the registration practice applicable where a company‘s articles of association provide for conditional capital both within a capital band and outside the capital band. This article sets out the resulting registration practice.

    Read more: EHRA CLARIFIES REGISTRATION PRACTICE FOR CONDITIONAL CAPITAL WITHIN AND OUTSIDE THE CAPITAL BAND 

  • Swiss advisers subject to the Swiss Anti-Money Laundering Act: Scope and Duties

    By

    Alexander Wherlock

    /

    Benjamin Leisinger

    Effective 1 October 2026, the revised Swiss Anti-Money Laundering Act will extend Switzerland‘s anti-money laundering framework to advisers participating professionally in covered transactions. Lawyers, notaries, fiduciaries, accountants, tax advisers, M&A advisers and other professionals may become subject to due-diligence, organizational and certain reporting requirements under the AML framework even if they do not execute financial transactions themselves. This article summarizes the new regime, its principal exemptions and its consequences for professional advisers.

    Read more: Swiss advisers subject to the Swiss Anti-Money Laundering Act: Scope and Duties

  • The Impact of Article 21c CRD VI on Swiss Banks‘ Loan Portfolios

    By

    Jürg Frick

    Effective as of 11 January 2027, CRD VI introduces an EU-wide restriction on third-country institutions‘ cross-border lending activities. Under the new article 21c CRD VI, Swiss banks may no longer extend loans, provide guarantees, or make credit commitments to EU-domiciled borrowers without an authorized subsidiary or branch in the relevant member state. The prohibition covers all corporate finance activities with an EU nexus, including syndicated credit facilities.

    Read more: The Impact of Article 21c CRD VI on Swiss Banks‘ Loan Portfolios

  • DocMorris Finance B.V.‘s Issuance of CHF 96.8 Million Senior Guaranteed Convertible Bonds Due 2031 and Concurrent Repurchase of Outstanding Convertible Bonds Due 2028

    By

    CapLaw

    On 11 September 2026, DocMorris Finance B.V., a directly wholly-owned subsidiary of DocMorris AG (SIX: DOCM), successfully completed the private placement of CHF 96.8 million 1.5 per cent. senior unsecured convertible bonds due 16 March 2031, unconditionally and irrevocably guaranteed by DocMorris AG and convertible into existing and/or newly issued registered shares of DocMorris AG. Concurrently with the new issuance, DocMorris AG completed the full repurchase of its outstanding 3.0 per cent. convertible bonds due August 2028 with a nominal amount of CHF 49.6 million through privately negotiated bilateral transactions. The repurchased bonds will be cancelled. The transaction reduced the…

    Read more: DocMorris Finance B.V.‘s Issuance of CHF 96.8 Million Senior Guaranteed Convertible Bonds Due 2031 and Concurrent Repurchase of Outstanding Convertible Bonds Due 2028